Lung Adenocarcinoma

Etiology

Tobacco smoking remains the leading risk factor for lung adenocarcinoma, though its relative contribution is lower for adenocarcinoma than for squamous cell carcinoma. Carcinogens in tobacco smoke, including polycyclic aromatic hydrocarbons and nitrosamines, cause direct DNA damage resulting in mutations across multiple oncogenes and tumor suppressor genes. Risk increases proportionally with cumulative exposure, measured in pack-years, and with both active and passive (secondhand) smoke inhalation.[1][2]

A substantial proportion of lung adenocarcinomas, estimated at 10% to 15% in the United States and considerably higher in East Asian populations, occur in never-smokers. Recognized nonsmoking risk factors of lung adenocarcinomas include:

• Radon gas exposure: the second leading cause of lung cancer in the United States, occurring through accumulation in poorly ventilated residential spaces
• Occupational exposures: asbestos, silica, arsenic, chromium, nickel, diesel exhaust, and polycyclic aromatic hydrocarbons
• Air pollution: both indoor (biomass fuel combustion, cooking fumes) and outdoor (PM2.5 particulate matter)
• Family history of lung cancer: suggesting heritable susceptibility, particularly relevant in never-smokers
• Prior lung disease: pulmonary fibrosis and other interstitial lung diseases confer elevated adenocarcinoma risk independent of smoking
• Prior thoracic radiation: especially relevant in survivors of lymphoma and breast cancer

Epidemiology

Lung cancer is the second most commonly diagnosed cancer in the United States, but ranks first in cancer-related mortality, accounting for more deaths annually than colorectal, breast, and prostate cancers combined. Approximately 234,580 new cases of lung and bronchial cancer were estimated in 2024, with over 125,070 deaths attributed to the disease.[1]

Adenocarcinoma has emerged as the most prevalent histologic subtype of NSCLC over the past 4 decades, surpassing squamous cell carcinoma, a shift attributed in part to changes in cigarette design (filter cigarettes promoting deeper inhalation into peripheral airways), declining smoking rates among men with a relative increase among women, and improved histologic characterization. The mean age at diagnosis is approximately 70 years, though adenocarcinoma is diagnosed in younger patients more frequently than other NSCLC subtypes.[1][2]

Overall, 5-year survival for lung cancer is approximately 25% across all stages, but highly stage-dependent: localized disease carries 60% to 70% 5-year survival, while distant metastatic disease drops to less than 8%. The implementation of low-dose CT screening in eligible high-risk populations has demonstrated a 20% to 24% reduction in lung cancer mortality in randomized trials.[1][4]

Pathophysiology

Lung adenocarcinoma arises through a stepwise progression from precursor lesions to invasive malignancy. The recognized preinvasive spectrum includes atypical adenomatous hyperplasia, adenocarcinoma in situ (AIS), and minimally invasive adenocarcinoma (MIA), before culminating in invasive adenocarcinoma. Adenomatous hyperplasia lesions are typically less than 5 mm. AIS and MIA carry near 100% and greater than 95% disease-specific survival with complete resection, respectively.[2]

At the molecular level, oncogenic driver alterations activate cell proliferation, survival, and metastatic pathways. Key clinically actionable alterations include:

• EGFR mutation (exon 19 del/exon 21 L858R) 
  • Overall survival of 15%–20%; in never-smokers and Asian patients 40%–50%
  • First-line treatment: osimertinib [1][5]

• KRAS mutation (most commonly G12C)
  • Overall survival of 25%–30%
  • Second-line targeted therapy with sotorasib or adagrasib now available [1][5]

• ALK rearrangement
  • Overall survival of 3%–7%; enriched in younger never-smokers
  • First-line: alectinib or brigatinib [1][5]

• ROS1 rearrangement
  • Overall survival of 1%–2%
  • Responsive to entrectinib or crizotinib [1][5]

• MET exon 14 skipping
  • Overall survival of 3%–4%
  • Actionable with capmatinib or tepotinib [1][5]

• BRAF V600E mutation
  • Overall survival of 1%–3%
  • Actionable with dabrafenib plus trametinib [1][5]

• RET rearrangement
  • Overall survival of 1%–2%
  • Actionable with selpercatinib or pralsetinib [1][5]

• NTRK fusion
  • Overall survival of <1%
  • Actionable with larotrectinib or entrectinib [1][5]

• HER2 mutation/amplification
  • Overall survival of 2%–4%
  • Trastuzumab deruxtecan (T-DXd) received FDA accelerated approval [1][5]

• PD-L1 expression
  • Approximately 30% high expressors (TPS ≥50%)
  • Predictive of immunotherapy response [1][5]

Tumors harboring these alterations often have mutually exclusive genomic profiles, reinforcing the importance of comprehensive, reflex molecular profiling at diagnosis rather than sequential single-gene testing. TP53 comutations are common across all subtypes.[1][5]

Tumors harboring these alterations often have mutually exclusive genomic profiles, reinforcing the importance of comprehensive, reflex molecular profiling at the time of diagnosis rather than sequential single-gene testing. TP53 comutations are common across all subtypes and can influence prognosis and treatment response.

Histopathology

The 2021 WHO Classification of Thoracic Tumors significantly revised the histologic taxonomy of lung adenocarcinoma, discontinuing older terms, eg, bronchoalveolar carcinoma, and introducing standardized nomenclature with prognostic relevance.[2] The current classification recognizes the following spectrum:

• Adenocarcinoma in situ: AIS involves a localized lesion ≤3 cm with pure lepidic growth along intact alveolar septa without stromal, vascular, or pleural invasion. Complete resection is associated with near 100% disease-specific survival.[2]
• Minimally invasive adenocarcinoma: MIA is predominantly lepidic adenocarcinoma ≤3 cm with ≤5 mm of invasion. Nearly uniformly curable with complete resection.[2]
• Invasive adenocarcinoma: This category is the most common and is further subtyped by predominant pattern: lepidic, acinar, papillary, micropapillary, and solid. Micropapillary and solid subtypes carry a worse prognosis.[2]
• Invasive mucinous adenocarcinoma: This type was formerly mucinous BAC. Invasive mucinous adenocarcinoma is typically consolidative and often multifocal, and is frequently KRAS-mutated.[2]
• Variants: This category includes colloid, fetal, and enteric adenocarcinoma subtypes.[2]

Immunohistochemistry is critical for classification. TTF-1 and napsin A confirm pulmonary adenocarcinoma lineage, whereas p40 and p63 expression argue against an adenocarcinoma diagnosis. Tumor spread through air spaces refers to the spread of tumor cells into surrounding airspaces beyond the edge of the main tumor, as recognized in the 2021 WHO classification. This tumor spread is associated with an increased risk of recurrence after limited resection and should be reported by pathologists when identified.[2]

History and Physical

Lung adenocarcinoma is frequently asymptomatic at presentation. The majority of early-stage cases are detected as incidental pulmonary nodules on CT imaging obtained for unrelated indications, representing both a diagnostic challenge and an opportunity for curative intervention. When symptoms are present, they typically reflect advanced locoregional extension or distant metastatic disease.[1]

Respiratory Symptoms

Respiratory symptoms commonly prompt the initial evaluation. Persistent cough is the most frequent presenting complaint and is often misattributed to alternative etiologies, contributing to diagnostic delay. Hemoptysis occurs less often in peripheral adenocarcinoma than in centrally located squamous cell carcinoma, but when present, it requires urgent evaluation. Dyspnea may reflect a large malignant pleural effusion, extensive parenchymal involvement, endobronchial obstruction, or lymphangitic carcinomatosis. Chest pain, typically pleuritic or positional, suggests pleural or chest wall involvement and should raise concern for locally advanced disease.

Constitutional Symptoms

Constitutional symptoms generally suggest advanced disease. Unintentional weight loss of 5% or more of body weight over 6 to 12 months is a red flag that warrants prompt diagnostic evaluation. Fatigue and anorexia commonly accompany advanced disease and may precede more specific respiratory or locoregional manifestations.

Signs of Locoregional Extension

Locoregional extension produces characteristic clinical findings that should prompt expedited evaluation. Superior vena cava syndrome manifests with facial plethora, upper extremity edema, and jugular venous distension due to mediastinal compression and may be the initial presenting feature. Horner syndrome, characterized by ptosis, miosis, and anhidrosis, results from apical tumor involvement of the cervical sympathetic chain, as in Pancoast tumors. Hoarseness arises from recurrent laryngeal nerve compression, most often on the left in association with aortopulmonary window or left-sided mediastinal disease. Phrenic nerve palsy leads to ipsilateral hemidiaphragm elevation on chest imaging and may significantly worsen dyspnea. Pericardial effusion due to direct cardiac invasion or pericardial metastasis can progress to cardiac tamponade and should be recognized as an oncologic emergency.

Paraneoplastic Syndromes

Paraneoplastic syndromes, although uncommon, carry important clinical implications. Hypertrophic pulmonary osteoarthropathy involves periosteal new bone formation, causing arthralgia and digital clubbing, and occurs more often in adenocarcinoma than in other NSCLC subtypes. Syndrome of inappropriate antidiuretic hormone secretion produces hyponatremia and may cause altered mental status. Hypercalcemia may result from parathyroid hormone–related peptide secretion or osteolytic bone metastases. Lambert-Eaton myasthenic syndrome occurs more commonly in small-cell lung cancer but can develop in adenocarcinoma.

Neurologic Symptoms

Brain metastases occur with particular frequency in lung adenocarcinoma, especially in tumors harboring EGFR mutations or ALK rearrangements, and may represent the initial manifestation of disease with headache, seizure, focal neurologic deficit, or cognitive changes. New neurologic symptoms in any patient with lung adenocarcinoma warrant prompt brain MRI evaluation.[1]

Evaluation

The evaluation of a patient with suspected lung adenocarcinoma adheres to the following logical 4-step sequence, in which each step has distinct goals and directly informs the next:

1. Nodule recognition and risk stratification
2. Systemic staging workup
3. Tissue acquisition
4. Comprehensive molecular profiling [1][3][4]

Step 1: Pulmonary Nodule Recognition and Risk Stratification

For most patients, the first step of the diagnostic journey begins with an incidentally detected pulmonary nodule. Lung adenocarcinoma typically arises in the lung periphery and remains asymptomatic in its earliest, most curable stages, underscoring the importance of appropriate nodule management by clinicians who order or interpret chest imaging.[3][4]

The Fleischner Society 2017 guidelines provided evaluation recommendations for incidentally detected nodules in patients aged 35 or older without known malignancy (see Table 1).[3]

Table 1. Fleischner Society 2017 Guidelines

Clinicians should note that subsolid and part-solid nodules grow more slowly than solid nodules but carry a higher malignant probability per unit size, particularly when a solid component is present or enlarging. Growth of the solid component is the most important trigger for tissue sampling.

Additionally, the Lung Imaging Reporting and Data System (Lung-RADS) is the standardized classification reporting system used by radiologists for CT lung cancer screening exams. A finding of Lung-RADS 3 or 4 warrants expedited referral to pulmonology or thoracic surgery for further evaluation.[4]

Step 2: Systemic Staging Workup

Once lung adenocarcinoma is confirmed or strongly suspected, the second step in the systematic staging evaluation is required before any treatment is initiated. The following studies should be completed efficiently, ideally within a coordinated interprofessional framework:

• CT of the chest and upper abdomen with IV contrast (including the adrenals) is required in all patients. This study defines tumor size, local invasion, mediastinal involvement, and adrenal metastases.
• A PET/CT is recommended for all patients without overt distant metastases. Detects occult nodal disease and distant metastases; guides mediastinal staging strategy.
• A brain MRI with contrast is recommended for tumors stage II and above, and in any patient with neurologic symptoms. The brain is a frequent and early metastatic site for adenocarcinoma, particularly EGFR-mutated and ALK-rearranged tumors.
• Pulmonary function testing (eg, spirometry, DLCO) is required before surgical resection. Predicted postoperative FEV1 and DLCO determine candidacy for lobectomy versus sublobar resection versus nonsurgical treatment.
• Mediastinal staging (EBUS-TBNA or mediastinoscopy) is mandatory when PET/CT suggests mediastinal nodal involvement. EBUS-TBNA is the preferred first-line procedure because this study is minimally invasive and highly accurate.
• A bone scan is typically performed only when a PET scan is unavailable and bony metastasis is clinically suspected.[1]

Step 3: Tissue Acquisition

Histologic confirmation is mandatory for definitive diagnosis and must provide sufficient tissue volume for both pathologic classification and comprehensive molecular profiling. Selection of the following biopsy approaches is individualized based on lesion location, size, proximity to vascular or pleural structures, patient comorbidities, particularly pulmonary reserve, and the need for concurrent mediastinal staging:

• CT-guided transthoracic needle biopsy (TTNB): This approach is preferred for peripheral lesions with adequate pleural distance and an acceptable risk of pneumothorax. High diagnostic yield (~90%) for accessible lesions. Pneumothorax occurs in 15% to 25% of cases; up to 5% require chest tube placement. Does not permit mediastinal staging in the same procedure.
• Conventional bronchoscopy (BAL, brushings, forceps biopsy): This biopsy procedure is appropriate for central or endobronchial lesions directly visible at bronchoscopy. Low yield (approximately 20%–30%) for peripheral adenocarcinomas.
• Advanced bronchoscopy (robotic-assisted, ENB, r-EBUS): Advanced bronchoscopy is used for peripheral lesions in which CT-guided biopsy carries an elevated risk. 
• Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA): For sampling of mediastinal and hilar lymph nodes, EBUS-TBNA may be performed to obtain simultaneous nodal staging and diagnosis in centrally located disease.
• Surgical biopsy (VATS or thoracotomy): When less-invasive approaches are nondiagnostic or technically infeasible, or when the surgical procedure itself is the definitive treatment.
• Liquid biopsy (plasma circulating tumor DNA/ctDNA): This biopsy approach may be performed when tissue is insufficient or inaccessible, as a complement to tissue next-generation sequencing, and for monitoring acquired resistance to targeted therapy. Sensitivity is lower than that of tissue biopsy for initial diagnosis.[1][6]

Advanced Bronchoscopy for Peripheral Pulmonary Lesions

Peripheral pulmonary lesions located beyond the reach of conventional bronchoscopy represent one of the most common and challenging scenarios in lung cancer diagnosis. Although CT-guided biopsy remains effective for accessible lesions, this approach carries a meaningful risk of pneumothorax and does not allow mediastinal staging during the same procedure. Over the past decade, advanced bronchoscopic platforms have expanded access to peripheral airways, where adenocarcinoma most frequently arises.[6]

Robotic-assisted bronchoscopy (RAB) represents the most recent and technologically advanced evolution in this space. Three FDA-cleared platforms are currently available: the Ion Endoluminal System (Intuitive Surgical), which uses fiber-optic shape-sensing technology to provide continuous catheter position awareness independent of fluoroscopy, the Monarch Platform (Auris/Ethicon), which employs electromagnetic navigation guidance and a joystick-controlled articulating bronchoscope, and the Galaxy System (Noah Medical, FDA-cleared 2023), which incorporates electromagnetic navigation with integrated digital tomosynthesis. Each platform generates a preprocedural CT-based airway pathway to the target lesion and provides real-time navigation feedback during biopsy, capabilities that significantly exceed those of conventional or electromagnetic navigation bronchoscopy (ENB) alone.

Key clinical evidence includes the BENEFIT trial (Monarch platform, multicenter) demonstrating a 96.2% lesion localization rate in its feasibility cohort, the PRECIsE study (Ion platform, multicenter) achieving a 97% biopsy completion rate in nodules with a median diameter under 20 mm without any pleural-based complications, the larger TARGET trial (Monarch, 679 patients, 2024) reporting a diagnostic yield of 63.8% using strict methodology and 76.6% by intermediate criteria with a median lesion size of 1.85 cm, and the ongoing CONFIRM study (Ion with cone-beam CT), which reported a preliminary strict diagnostic yield of 89% with no pneumothorax events in 155 patients, the highest yield reported to date under rigorous methodology. Reported pneumothorax rates across RAB studies are consistently lower than those of CT-guided biopsy, typically between 1% and 4%.[6]

An important limitation shared by all RAB platforms is CT-to-body divergence, which is the discrepancy between the preprocedural CT used for pathway planning and the patient's actual intraprocedural anatomy due to differences in respiratory phase, patient positioning, and airway dynamics under general anesthesia. Integration of intraprocedural imaging, including cone-beam CT (CBCT) and mobile 3D fluoroscopy, has emerged as the most effective strategy for confirming true tool-in-lesion position before sampling, driving diagnostic yields into the high 80% to 90% range even for small lesions under 20 mm. When CT-guided biopsy is high-risk due to severe emphysema, bullous disease, anticoagulation, or lesion proximity to vascular structures, RAB with intraprocedural imaging represents the preferred bronchoscopic alternative and should be available as part of any comprehensive lung nodule program.[6]

Notably, a key advantage of RAB over CT-guided biopsy is the ability to perform same-session EBUS-TBNA for mediastinal lymph node staging, combining peripheral tissue acquisition and nodal staging in a single anesthetic event. This integrated approach reduces time to diagnosis, avoids repeated procedures, and is particularly valuable when both a peripheral nodule and mediastinal adenopathy require characterization.

Step 4: Comprehensive Molecular Profiling

Tissue diagnosis alone is insufficient for the management of lung adenocarcinoma. Current guidelines from NCCN, ASCO, and the College of American Pathologists (CAP) mandate comprehensive molecular profiling for all patients with non-squamous NSCLC at diagnosis of advanced or metastatic disease. Next-generation sequencing panels, rather than sequential single-gene assays, are strongly preferred as these studies are faster, more tissue-efficient, and more likely to detect all actionable alterations.[1][5]

The following are the minimum required biomarkers and their clinical significance:

• EGFR (exon 19 del, exon 21 L858R): most common actionable mutation; determines eligibility for first-line osimertinib and adjuvant osimertinib in resected disease [1][5][7]
• ALK rearrangement: highly responsive to ALK inhibitors; must not be missed [1][5]
• KRAS G12C: now second-line actionable with sotorasib or adagrasib; most common mutation in lung adenocarcinoma overall [1][5]
• PD-L1 (TPS) — Determines immunotherapy eligibility and first-line regimen selection for driver-negative tumors [1,2,8]
• ROS1, MET, BRAF, RET, NTRK, HER2: each has an approved targeted therapy; missed alterations equal missed treatment opportunities [1][5]
• TMB (tumor mutational burden): higher TMB may predict immunotherapy benefit; increasingly included in next-generation sequencing panels [1][5]

Molecular profiling should now be considered for resected early-stage adenocarcinoma as well — EGFR testing is standard to determine eligibility for adjuvant osimertinib (ADAURA trial, OS HR 0.49, P <0.001).[7]

Treatment / Management

Early-Stage Disease (Stages I to IIIA)

Surgical resection is the treatment of choice for operable patients with stage I to IIIA adenocarcinoma. Anatomic lobectomy with systematic mediastinal lymph node dissection or sampling remains the standard. Sublobar resection (segmentectomy or wedge) is increasingly accepted for small peripheral tumors (≤2 cm) in patients with limited pulmonary reserve, based on the JCOG0802 and CALGB 140503 trials, which demonstrated the noninferiority of segmentectomy for select T1 tumors.[1](A1)

Adjuvant therapy decisions are now molecularly informed by the following:

• Osimertinib (ADAURA trial): approved for adjuvant therapy in resected stage IB to IIIA EGFR-mutated NSCLC. Final overall survival analysis demonstrated a 5-year overall survival of 88% with osimertinib versus 78% with placebo (HR 0.49; P <0.001) [7]
• Alectinib (ALINA trial): positive results for disease-free survival in resected ALK-rearranged NSCLC; emerging standard [1]
• Atezolizumab (IMpower010): approved as adjuvant immunotherapy for resected stage II to IIIA NSCLC with PD-L1 TPS ≥1% after adjuvant chemotherapy [1][8]
• Platinum-based adjuvant chemotherapy: remains standard for stage II to IIIA disease without targetable mutations [1]
(A1)

For medically inoperable early-stage disease, stereotactic body radiation therapy (SBRT/SABR) offers excellent local control and represents the standard of care for patients who cannot undergo surgery.[1] (A1)

Locally Advanced Disease (Stages IIIB–IIIC)

Unresectable stage III disease is managed with concurrent chemoradiation followed by consolidation durvalumab (anti-PD-L1) in patients without disease progression, the PACIFIC regimen. The 5-year follow-up of the PACIFIC trial demonstrated overall survival of 42.9% with durvalumab versus 33.4% with placebo (HR 0.72), establishing a new benchmark for the standard of care in this setting.[8]

Metastatic Disease (Stage IV) Targeted Therapy

For patients with actionable driver mutations, targeted therapy is first-line treatment, consistently demonstrating superior response rates, progression-free survival, and tolerability compared to chemotherapy.[1][5] Targeted therapies include:(A1)

• EGFR-mutated NSCLC
  • Osimertinib (third-generation TKI) first-line (superior CNS penetration and activity against T790M resistance) [1][5][7]
• ALK-rearranged NSCLC
  • Alectinib or brigatinib first-line over crizotinib (improved intracranial activity)
  • Lorlatinib is preferred for CNS disease or after second-generation inhibitor failure [1][5]
• ROS1-rearranged NSCLC
  • Entrectinib or crizotinib
  • Lorlatinib for resistance [1][5]
• KRAS G12C
  • Sotorasib or adagrasib (second-line)
  • First targeted therapies for this historically untreatable mutation [1][5]
• MET exon 14 skipping: Capmatinib or tepotinib [1][5]
• BRAF V600E: Dabrafenib plus trametinib [1][5]
• RET rearrangement: Selpercatinib or pralsetinib [1][5]
• NTRK fusion: Larotrectinib or entrectinib [1][5]
• HER2 mutation
  • Trastuzumab deruxtecan (T-DXd)
  • FDA accelerated approval [1][5]
(A1)

Metastatic Disease (Stage IV) Immunotherapy

For patients without actionable driver mutations, the following PD-L1 expression guides immunotherapy decisions: [1,2,8]

• PD-L1 TPS ≥50% — Pembrolizumab monotherapy is a standard first-line option.[1][5][8]
• PD-L1 TPS 1–49% — Pembrolizumab plus platinum-based chemotherapy preferred over chemotherapy alone. [1,2,8]
• PD-L1 TPS <1% — Platinum-based chemotherapy with pembrolizumab; combinations still generally outperform chemotherapy alone. [1][5][8]
(A1)

Understanding that immunotherapy should NOT be used first-line in patients with sensitizing EGFR, ALK, or other targetable driver mutations is critical, as this approach is substantially less effective and potentially harmful.[1][5][8] Following treatment, patients require ongoing surveillance with a CT chest every 6 months for 2 years, then annually. Brain MRI surveillance is appropriate for EGFR-mutated and ALK-rearranged tumors, given the high propensity for CNS metastases.[1](A1)

Differential Diagnosis

When evaluating a pulmonary nodule or mass with imaging or pathologic features suggestive of adenocarcinoma, the differential diagnoses include:

• Squamous cell carcinoma of the lung: central location, more strongly associated with smoking, p40/p63 positive, TTF-1 negative
• Large cell carcinoma
  • Lacks glandular or squamous differentiation on immunohistochemistry
  • Diagnosis of exclusion
• Small cell lung cancer (SCLC) 
  • Central location, neuroendocrine morphology, rapid growth, paraneoplastic syndromes
  • TTF-1 positive, but synaptophysin/chromogranin distinguish from adenocarcinoma
• Pulmonary carcinoid tumor
  • Neuroendocrine origin
  • Lower metabolic activity on PET
  • Typically younger patients
• Pulmonary metastases from extrathoracic primaries: especially colorectal (CK20+/CK7–), breast (GATA3+), renal cell, melanoma (S100+/MART-1+), thyroid (TTF-1+/thyroglobulin+)
• Infectious granulomatous disease 
  • Histoplasmosis, coccidioidomycosis, tuberculosis
  • May produce nodules with PET avidity mimicking malignancy
  • Tissue or serologic diagnosis required
• Sarcoidosis: bilateral hilar adenopathy, noncaseating granulomas on biopsy, ACE elevation
• Organizing pneumonia
  • Consolidation or nodular infiltrates mimicking malignancy
  • May respond to corticosteroids
  • Biopsy shows Masson bodies
• Pulmonary hamartoma
  • Benign
  • Characteristic "popcorn" calcification on CT
  • No FDG avidity on PET

Surgical Oncology

Surgical resection is the treatment of choice for patients with stage I to stage IIIA lung adenocarcinoma who have adequate cardiopulmonary reserve and no prohibitive comorbidities. Anatomic lobectomy with systematic mediastinal lymph node dissection or sampling remains the oncologic standard, offering the best combination of local control and accurate pathologic staging. Minimally invasive approaches, including video-assisted thoracoscopic surgery (VATS) and robotic-assisted thoracic surgery (RATS), are preferred when technically feasible, demonstrating equivalent oncologic outcomes with significantly reduced morbidity, shorter hospital stays, and faster return to baseline function compared to open thoracotomy.[1]

Sublobar resection, segmentectomy or wedge resection, is increasingly accepted for select patients with peripheral tumors 2 cm or less, based on the JCOG0802 and CALGB 140503 trials demonstrating noninferiority of segmentectomy over lobectomy in appropriately selected T1 tumors. Wedge resection is generally reserved for patients with severely limited pulmonary reserve in whom even segmentectomy would result in functionally prohibitive postoperative impairment.[1]

Adjuvant therapy decisions are now molecularly informed and represent one of the most significant paradigm shifts in thoracic oncology. EGFR mutation testing is now standard for all resected adenocarcinomas, and patients with EGFR exon 19 deletion or exon 21 L858R mutation who undergo complete resection of stage IB to IIIA disease should be offered adjuvant osimertinib for 3 years. The ADAURA trial demonstrated a 5-year overall survival of 88% with osimertinib versus 78% with placebo (HR 0.49; P <0.001).[7] Platinum-based adjuvant chemotherapy remains standard for stage II to IIIA disease without targetable mutations. Atezolizumab is approved as adjuvant immunotherapy for resected stage II to IIIA NSCLC with PD-L1 TPS ≥1% following adjuvant chemotherapy (IMpower010).[1][8]

Pneumonectomy, removal of the entire lung, is occasionally required for centrally located tumors but carries substantially higher perioperative morbidity and mortality than lobectomy and should only be performed when lesser resections are not oncologically feasible. Mediastinal lymph node dissection at the time of resection is important both for accurate pathologic staging and potential therapeutic benefit.[1]

Radiation Oncology

Radiation therapy plays a critical role across multiple stages of lung adenocarcinoma management, from curative-intent treatment of early-stage inoperable disease to definitive therapy for locally advanced unresectable disease and palliation of metastatic complications.

For medically inoperable patients with early-stage (stage I–II) lung adenocarcinoma, stereotactic body radiation therapy (SBRT), also called stereotactic ablative radiotherapy (SABR), is the standard of care. SBRT delivers high doses of precisely targeted radiation, typically 54 Gy in 3 fractions, 50 Gy in 5 fractions, or equivalent biologically effective doses depending on tumor location and proximity to critical structures, achieving local control rates exceeding 90% at 3 years. Toxicities include radiation pneumonitis, chest wall pain, and rare rib fractures for peripherally located tumors. Tumors adjacent to central airways require modified fractionation schemes to reduce the risk of serious bronchial complications.[1]

For unresectable stage III (IIIB–IIIC) lung adenocarcinoma, the standard of care is concurrent platinum-based chemoradiation followed by consolidation durvalumab immunotherapy, the PACIFIC regimen. Concurrent chemoradiation delivers a total radiation dose of approximately 60 to 66 Gy in 30 to 33 fractions. Durvalumab consolidation, administered for up to 12 months in patients without disease progression after chemoradiation, significantly improves both overall survival and progression-free survival. The 5-year follow-up of the PACIFIC trial demonstrated overall survival of 42.9% in the durvalumab group versus 33.4% with placebo, establishing a new benchmark for the standard of care in this setting.[8]

Palliative radiation is valuable for symptomatic metastatic disease, including painful bone metastases, brain metastases not amenable to stereotactic radiosurgery (SRS), spinal cord compression, and airway obstruction from endobronchial tumors. For patients with limited brain metastases, SRS is preferred over whole-brain radiation to preserve neurocognitive function, particularly for patients with EGFR-mutated or ALK-rearranged disease who may have prolonged survival on targeted therapy.[1]

Pertinent Studies and Ongoing Trials

Several of the following landmark clinical trials have defined the current standard of care in lung adenocarcinoma and continue to shape evolving practice: 

• ADAURA (NCT02511106)
  • Phase 3; osimertinib versus placebo as adjuvant therapy in resected stage IB to IIIA EGFR-mutated NSCLC
  • Final overall survival analysis published NEJM 2023: 5-year overall survival 88% vs 78%, HR 0.49, P <0.001
  • Established adjuvant osimertinib as standard of care [7]
• PACIFIC (NCT02125461)
  • Phase 3; durvalumab versus placebo following concurrent chemoradiation in unresectable stage III NSCLC
  • The 5-year overall survival 42.9% versus 33.4%, HR 0.72
  • Established the PACIFIC regimen as the global standard of care [8]
• ALINA (NCT03456076)
  • Phase 3; alectinib as adjuvant therapy in resected ALK-rearranged NSCLC
  • Demonstrated significant DFS benefit
  • Pending overall survival maturity
• KEYNOTE-189 (NCT02578680)
  • Phase 3; pembrolizumab plus pemetrexed plus platinum versus chemo alone in metastatic nonsquamous NSCLC
  • Established chemoimmunotherapy as the first-line standard for driver-negative disease
• JCOG0802/WJOG4607L
  • Phase 3; segmentectomy versus lobectomy for small peripheral stage IA NSCLC ≤2 cm
  • Demonstrated superior relapse-free survival and noninferior overall survival with segmentectomy, supporting sublobar resection in select patients
• TARGET Trial (NCT04182815)
  • Prospective multicenter study of Monarch robotic bronchoscopy in 679 patients
  • Strict diagnostic yield 63.8%
  • Median lesion 1.85 cm [6]
• CONFIRM study
  • Ion robotic bronchoscopy plus cone-beam CT
  • Preliminary 89% strict diagnostic yield, zero pneumothorax
  • Currently  ongoing [6]
• ADAURA2 (NCT05120349)
  • Ongoing phase 3 evaluating adjuvant osimertinib for stage IA2 to IA3 EGFR-mutated NSCLC
  • Results pending
• NeoADAURA (NCT04351555)
  • Phase 3; neoadjuvant osimertinib ± chemotherapy versus chemotherapy alone in resectable EGFR-mutated NSCLC
  • Results pending

Treatment Planning

Radiation treatment planning for lung adenocarcinoma varies significantly by clinical indication, curative-intent early-stage, definitive locally advanced, or palliative, and requires close collaboration between radiation oncologists, medical physicists, and dosimetrists.[1]

Stereotactic Body Radiation Therapy for Early-Stage Inoperable Disease

Simulation is performed with 4-dimensional CT (4D-CT) to capture respiratory motion across the breathing cycle. The internal gross tumor volume (IGTV) encompasses the tumor's full range of motion; a planning target volume (PTV) margin of 3 to 5 mm is added to account for setup uncertainty. Common dose-fractionation SBRT and SABR regimens include:

• Peripheral tumors: 54 Gy in 3 fractions; 50 Gy in 5 fractions; 60 Gy in 5 fractions
• Central tumors (within 2 cm of the proximal bronchial tree): risk-adapted regimens, eg, 50 Gy in 5 fractions or 60 Gy in 8 fractions to reduce airway toxicity risk
• Biologically effective dose (BED): ≥100 Gy is associated with improved local control

Volumetric modulated arc therapy (VMAT) or intensity-modulated radiation therapy (IMRT) is used to achieve steep dose gradients that protect adjacent normal structures. Respiratory gating or breath-hold techniques may be employed to minimize treated volume. Cone-beam CT image guidance is performed at each fraction.[1]

Definitive Chemoradiation for Unresectable Stage III Disease

Simulation with 4D-CT, involving PET/CT fusion for target delineation, is standard practice. Gross tumor volume (GTV) encompasses the primary tumor and PET-avid or CT-confirmed involved nodes. Clinical target volume (CTV) encompasses the GTV with a margin for microscopic extension; PTV adds a setup uncertainty margin (typically 5–10 mm). Elective nodal irradiation is generally not performed in current practice, as involved-field radiation reduces toxicity without compromising outcomes.

The total prescription dose is 60 to 66 Gy delivered in 30 to 33 daily fractions of 1.8 to 2 Gy. IMRT or VMAT is preferred over 3D conformal radiation therapy (3DCRT) for stage III disease, as it significantly reduces mean lung dose, V20 (volume of lung receiving ≥20 Gy), and esophageal dose, translating to lower rates of radiation pneumonitis and esophagitis. Concurrent chemotherapy (typically carboplatin plus paclitaxel or cisplatin plus etoposide) is administered during radiation. Following completion without progression, consolidation durvalumab is initiated.[1]

Palliative Radiation

Targets are defined clinically based on the site of symptomatic disease. Common regimens include 30 Gy in 10 fractions or 20 Gy in 5 fractions for bone metastases, 20 to 30 Gy in 5 to 10 fractions for thoracic palliation (hemoptysis, SVC syndrome, and airway obstruction). Whole-brain radiation therapy (WBRT), when used, is typically 30 Gy in 10 fractions. SRS is preferred over WBRT for patients with 4 or fewer brain metastases and good performance status to preserve neurocognitive function.[1]

Toxicity and Adverse Effect Management

Systemic therapy for lung adenocarcinoma requires careful pharmacologic management across multiple drug classes with distinct toxicity profiles. Pharmacists and advanced practitioners play a critical role in identifying drug interactions, ensuring appropriate dose modifications, and counseling patients on adherence and toxicity recognition.[1][5]

EGFR Tyrosine Kinase Inhibitors

Adverse effects associated with agents, eg, osimertinib, erlotinib, gefitinib, afatinib, include:

• Common adverse effects
  • Acneiform rash (most common, treat with topical clindamycin plus oral doxycycline)
  • Diarrhea (loperamide; dose-reduce if grade 3+)
  • Paronychia
  • Stomatitis
  • Dry skin
• Serious adverse effects
  • Interstitial lung disease (ILD/pneumonitis, incidence 3% to 4%, hold drug immediately if suspected, can be fatal)
  • QTc prolongation (osimertinib)
  • Cardiomyopathy (afatinib, rare)
• Key drug interactions
  • Osimertinib: avoid strong CYP3A4 inducers (rifampin reduces exposure by approximately 80%; avoid carbamazepine, phenytoin, St. John's Wort)
  • CYP3A4 inhibitors have a modest effect
• Patient counseling
  • Take at the same time daily
  • Avoid grapefruit
  • Do not crush tablets
  • Report new dyspnea or cough immediately
  • Sun protection for rash

ALK/ROS1 Inhibitors 

Adverse effects associated with agents, eg, alectinib, brigatinib, lorlatinib, crizotinib, include:

• Common adverse effects
  • Peripheral edema
  • Constipation
  • Elevated transaminases
  • Bradycardia
  • Visual disturbances with crizotinib
  • Weight gain with lorlatinib
  • Hyperlipidemia with lorlatinib

• Serious adverse effects
  • Interstitial lung disease and pneumonitis (monitor closely, especially early)
  • Hepatotoxicity (monitor liver function tests monthly for first 3 months)
  • Central nervous system effects with lorlatinib, including cognitive changes and mood disorders
  • Counsel patients and caregivers regarding CNS changes

• Key drug interactions
  • Alectinib and brigatinib: strong CYP3A4 inducers, eg, rifampin, significantly reduce exposure
  • Avoid coadministration with lorlatinib
  • Rifampin is absolutely contraindicated due to severe exposure reduction

Immune Checkpoint Inhibitors 

Adverse effects and management associated with agents, eg, pembrolizumab, durvalumab, atezolizumab, include:

• Mechanism-related toxicities (immune-related adverse events)
  • Immune-related pneumonitis (most feared in lung cancer; grade 3 or higher requires holding therapy and systemic corticosteroids)
  • Colitis
  • Hepatitis
  • Endocrinopathies (hypothyroidism is the most common; manage with hormone replacement)
  • Myocarditis (rare but life-threatening)
  • Dermatitis

• Management
  • Grade 1: monitor
  • Grade 2: hold the drug, consider corticosteroids
  • Grade 3–4: permanently discontinue therapy, initiate high-dose corticosteroids (prednisone 1–2 mg/kg/day), and add immunosuppression, eg, infliximab or mycophenolate for steroid-refractory cases

• Patient counseling
  • Immune-related adverse events may occur at any time, including months after completion
  • Instruct patients to report new rash, diarrhea, shortness of breath, muscle weakness, or vision changes immediately

Key Formulary and Adherence Considerations

Additional considerations when administering systemic therapy include:

• Oral targeted therapies: All are outpatient oral agents requiring strict adherence. Missed doses may allow tumor regrowth. Patient assistance programs are available for financial support.
• Generic availability: Erlotinib and gefitinib now have generic formulations. Osimertinib and alectinib remain branded as of 2024.
• Specialty pharmacy coordination: Most targeted therapies require specialty pharmacy dispensing; pharmacist involvement in refill management, prior authorization, and patient monitoring is essential.

Medical Oncology

Systemic therapy selection in lung adenocarcinoma is driven by molecular profile, disease stage, and performance status. For patients with actionable driver mutations, targeted therapy is first-line treatment and consistently demonstrates superior response rates, progression-free survival, and tolerability compared to chemotherapy or immunotherapy.[1][5]

For EGFR-mutated NSCLC (exon 19 deletion or exon 21 L858R), osimertinib, a third-generation EGFR tyrosine kinase inhibitor, is the first-line standard of care due to its superior central nervous system penetration, activity against the T790M resistance mutation, and favorable tolerability profile. For ALK-rearranged NSCLC, alectinib or brigatinib are preferred first-line agents over crizotinib based on improved intracranial activity and progression-free survival; lorlatinib is preferred for CNS-predominant disease or after second-generation inhibitor failure. Additional actionable targets with approved therapies include ROS1 (entrectinib, crizotinib), KRAS G12C (sotorasib or adagrasib as a second-line), MET exon 14 skipping (capmatinib, tepotinib), BRAF V600E (dabrafenib plus trametinib), RET rearrangement (selpercatinib, pralsetinib), NTRK fusion (larotrectinib, entrectinib), and HER2 mutation (trastuzumab deruxtecan).[1][5]

For patients without actionable driver mutations, PD-L1 expression guides immunotherapy selection. For PD-L1 TPS or 50% or greater, pembrolizumab monotherapy is a standard first-line option. For PD-L1 TPS 1% to 49%, pembrolizumab plus platinum-based chemotherapy (carboplatin/pemetrexed) is preferred over chemotherapy alone. For PD-L1 TPS less than 1%, platinum-based chemoimmunotherapy combinations still generally outperform chemotherapy alone. Immunotherapy must not be used first-line in patients with sensitizing EGFR, ALK, or other targetable driver mutations, as this treatment is substantially less effective and may cause excess toxicity in this population.[1][5][8]

For unresectable stage III disease, the standard of care is concurrent platinum-based chemoradiation followed by consolidation durvalumab for up to 12 months in patients without progression, the PACIFIC regimen. The 5-year overall survival was 42.9% with durvalumab versus 33.4% with placebo.[8]

Surveillance after systemic therapy includes a CT chest every 6 months for 2 years, then annually. Brain MRI surveillance is appropriate for EGFR-mutated and ALK-rearranged patients given the high propensity for CNS metastases. Repeat molecular profiling at disease progression is critical to identify acquired resistance mechanisms, eg, EGFR T790M on first- or second-generation TKI, that may guide subsequent therapy selection.[1][5]

Staging

Lung adenocarcinoma is staged according to the Eighth Edition TNM Classification (see Table 2). Accurate clinical and pathologic staging is mandatory before initiating any treatment, as it directly determines surgical candidacy, radiation planning, systemic therapy selection, and prognosis.[1]

The TNM system characterizes tumors along 3 independent dimensions: T (primary tumor size and local extent), N (regional lymph node involvement), and M (distant metastasis). Understanding each component individually makes the overall staging framework easier to apply clinically.[1]

Primary Tumor (T)

The T descriptor reflects both tumor size and the degree of local invasion. As tumors grow larger and invade adjacent structures, the T category increases:

 Table 2. Tumor Classification

A helpful memory tip for clinicians frames T1 and T2 tumors as contained within or near the lobe, T3 tumors as touching the chest wall or presenting with same-lobe satellite nodules, and T4 tumors as involving the mediastinum or crossing into another lobe. Size thresholds further clarify staging distinctions: T1 tumors measure 3 cm or less; T2 tumors measure greater than 3 cm but up to 5 cm; T3 tumors measure greater than 5 cm but up to 7 cm; and T4 tumors measure greater than 7 cm or demonstrate deep invasion into adjacent structures.

Regional Lymph Nodes (N)

The N descriptor reflects the location of lymph node involvement. This is the single most important prognosticator for resectability, as N2 disease is often the dividing line between potentially resectable and unresectable disease, and N3 renders a patient unresectable in virtually all circumstances (see Table 3).

Table 3. Nodal Classification

A useful memory tip for nodal staging begins with N0, which indicates no regional lymph node involvement. N1 refers to metastasis to the ipsilateral hilar nodes on the same side and relatively close to the primary tumor. N2 describes spread to ipsilateral mediastinal nodes, reflecting deeper and more central involvement on the same side. N3 represents the most advanced nodal category, involving contralateral mediastinal or hilar nodes, or supraclavicular nodes above the collarbone. As nodal spread progresses farther from the primary site, becomes more central, or crosses to the opposite side, prognosis generally worsens.

Distant Metastasis (M)

The M descriptor distinguishes localized from disseminated disease. The eighth edition introduced important granularity that separates oligometastatic disease (M1b) from widely metastatic disease (M1c), which has clinical relevance for emerging oligometastasis-directed treatment strategies (see Table 4).

 Table 4. Metastasis Classification

A practical memory tip for metastatic staging begins with M0, indicating disease confined to the primary site without distant spread. M1a describes spread within the chest, eg, involvement of the contralateral lung, pleura, or malignant pleural effusion. M1b refers to a single metastatic focus outside the chest, often characterized as oligometastatic disease. M1c denotes multiple metastatic sites outside the chest, reflecting widely metastatic disease. The distinction between M1b and M1c carries important therapeutic implications, as patients with oligometastatic disease may benefit from local ablative therapy in addition to systemic treatment.

Stage Groupings 

Once T, N, and M are assigned individually, they combine to form a final-stage group. The stage group determines the overall treatment strategy: surgery for early stages, combined modality for locally advanced stages, and systemic therapy for metastatic disease. A 5-year survival estimate is approximate and reflects contemporary data (see Table 5)

 Table 5. Staging and 5-Year Prognosis

 A key clinical pearl clinicians should keep in mind involves recognizing the major inflection points in staging and management. N2 disease represents the edge of resectability and warrants careful interprofessional discussion, whereas N3 disease is considered unresectable. M1b indicates oligometastatic spread and may permit consideration of local therapy in select patients. For early-stage disease, stages I through IIA are generally managed with surgery alone or surgery followed by adjuvant therapy. Stages IIB through IIIA typically require surgery combined with multimodal treatment. Stages IIIB through IIIC are managed with definitive chemoradiation, while stage IV disease is treated primarily with systemic therapy.

Prognosis

The prognosis of lung adenocarcinoma is highly stage-dependent and has improved substantially over the past decade with the advent of molecularly targeted therapies and immune checkpoint inhibitors, though overall outcomes remain poor due to the preponderance of advanced-stage diagnoses.[1]

The following are stage-specific 5-year survival estimates:

• Stage 0 (AIS): apprxomately 100% with complete resection
• Stage IA1–IA3: 77%–92% with surgery
• Stage IB–IIA: 60%–73% with surgery ± adjuvant therapy
• Stage IIB–IIIA: 26%–53%; multimodal therapy required
• Stage IIIB–IIIC: 10%–24%; chemoradiation + durvalumab standard
• Stage IVA–IVB: <10%; systemic therapy prolongs survival but is rarely curative [1]

Impact of Molecular Profile on Prognosis

The identification of actionable driver mutations has transformed the prognosis of metastatic lung adenocarcinoma for affected subgroups. Patients with EGFR-mutated NSCLC treated with osimertinib achieve a median progression-free survival of approximately 18 to 20 months and a median overall survival exceeding 38 months in first-line trials, far surpassing outcomes with chemotherapy alone. Similarly, patients with ALK-rearranged NSCLC treated with alectinib achieve a median PFS approaching 35 months. These figures represent the best outcomes currently achievable in metastatic NSCLC.[1][5]

For early-stage EGFR-mutated disease, the ADAURA trial established that adjuvant osimertinib reduces the risk of death by 51% compared to placebo (HR 0.49; 5-year overall survival 88% vs 78%), representing a significant improvement in the curative-intent setting.[7]

Factors associated with worse prognosis include advanced stage at diagnosis, poor performance status, absence of an actionable driver mutation, solid or micropapillary predominant histology, high tumor mutational burden in immunotherapy-ineligible settings, presence of brain metastases at diagnosis, and ALK/EGFR-negative driver-negative status.[1][2]

Factors associated with better prognosis include early-stage disease with complete surgical resection, presence of an actionable driver mutation with available targeted therapy, never-smoker status (associated with higher rates of targetable alterations), lepidic-predominant histology on resection, and high PD-L1 expression in driver-negative tumors managed with immunotherapy.[1][5][2]

Despite advances, lung adenocarcinoma remains the leading cause of cancer death in the United States. The majority of patients are diagnosed at an advanced stage, and while survival has improved measurably, particularly for molecularly defined subgroups, median overall survival in unselected metastatic disease remains approximately 12 to 18 months. Continued investment in early detection through lung cancer screening and novel therapeutic strategies remains essential.[1]

Complications

Disease-related complications include:

• Malignant pleural effusion: occurs in up to 40% of patients; causes dyspnea and reduced quality of life; managed with therapeutic thoracentesis, indwelling pleural catheter (IPC), or pleurodesis
• Malignant pericardial effusion: may cause cardiac tamponade; requires pericardiocentesis or surgical pericardial window
• Endobronchial obstruction: causes atelectasis, postobstructive pneumonia, and hemoptysis; treated bronchoscopically with laser, argon plasma coagulation, cryotherapy, or airway stenting
• Massive hemoptysis: life-threatening; managed with interventional bronchoscopy (balloon tamponade, electrocautery) or bronchial artery embolization; rigid bronchoscopy may be required
• Superior vena cava syndrome: mediastinal tumor compression; managed with systemic therapy ± endovascular stenting for rapid symptom relief
• Malignant spinal cord compression: vertebral metastases causing epidural compression; requires emergent MRI, high-dose dexamethasone, radiation oncology, and neurosurgery consultation
• Hypercalcemia of malignancy: intravenous hydration, bisphosphonates (zoledronic acid) or denosumab; treat underlying malignancy

Treatment-related complications include:

• Surgical: air leak, the most common postthoracotomy complication; managed with water-seal drainage; prolonged air leak (>5 days) may require endobronchial valve or surgical intervention
• Chemotherapy: febrile neutropenia is common, treat promptly with broad-spectrum antibiotics; consider prophylactic G-CSF in high-risk regimens
• EGFR TKI: ILD/pneumonitis, immediately hold drug; high-dose corticosteroids; consider pulmonology consultation; do not rechallenge with the same agent
• Immunotherapy: pneumonitis is the most dangerous irAE in lung cancer patients who already have compromised pulmonary reserve; grade 2+ requires drug hold and systemic corticosteroids
• Immunotherapy: endocrine irAEs, eg, hypothyroidism (lifelong thyroid hormone replacement); adrenal insufficiency (physiologic steroid replacement); immune-mediated diabetes (insulin)
• SBRT: radiation pneumonitis typically occurs 1 to 6 months after treatment; presents with cough, dyspnea, and low-grade fever; treated with corticosteroids if symptomatic